Profile data is unavailable for this security.
About the company
Solara Active Pharma Sciences Limited is an India-based global, pureplay active pharmaceutical ingredients (API) company. The Company is engaged in the manufacturing and development of APIs and offers contract manufacturing and development services for global companies. Its commercial product category includes Albendazole, Aprepitant (Antiemetic), Colchicine, Citicoline Sodium, Disulfiram, Dolutegravir, Etomidate, Flucytosine, Ibuprofen Arginine, Lurasidone Hydrochloride, Rifaximin, Tioconazole, Zileuton and others. Its research and development (R&D) product category includes Brivaracetam, Flecainide Acetate, Naproxen Base, Obeticholic acid, Patiromer Sorbitex Calcium, Rotigotine, Safinamide, Sapropterin, Sugammadex, Tranexamic Acid, Sucroferric Oxyhydroxide and others. Its business is spread across 70 countries with operations in the key markets of North America, Europe, Japan, South Korea and the Middle East and North Africa. It has one R&D center in Chennai.
- Revenue in INR (TTM)12.55bn
- Net income in INR-191.10m
- Incorporated2017
- Employees1.78k
- LocationSolara Active Pharma Sciences Ltd3rd & 4th Floor, Batra CentreNo.28, Sardar Patel Road, GuindyCHENNAI 600127IndiaIND
- Phone+91 2 227892924
- Fax+91 2 227892942
- Websitehttps://solara.co.in/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hester Biosciences Ltd | 3.14bn | 409.47m | 13.31bn | 562.00 | 41.52 | -- | 22.32 | 4.23 | 37.69 | 37.69 | 277.25 | -- | -- | -- | -- | 5,594,555.00 | -- | 5.39 | -- | 6.72 | 73.52 | 64.87 | 13.51 | 11.44 | -- | 9.65 | -- | 23.77 | 2.15 | 11.16 | 45.52 | -1.18 | -22.47 | 1.18 |
| Beta Drugs Ltd | 3.86bn | 464.68m | 13.87bn | 399.00 | 19.70 | 6.27 | 22.64 | 3.60 | 69.72 | 65.19 | 509.33 | 218.94 | 0.986 | 3.64 | 3.48 | 9,665,303.00 | 11.88 | 15.08 | 16.29 | 21.53 | 39.79 | 40.30 | 12.05 | 12.72 | 2.45 | 5.13 | 0.3974 | 0.00 | 22.54 | 31.89 | 28.96 | 37.92 | 19.23 | -- |
| Ngl Fine Chem Ltd | 4.47bn | 353.73m | 14.07bn | 456.00 | 39.77 | -- | 26.43 | 3.15 | 57.26 | 57.26 | 723.35 | -- | -- | -- | -- | 9,799,871.00 | -- | 13.34 | -- | 17.44 | 51.62 | 41.63 | 7.92 | 12.15 | -- | 9.06 | -- | 2.85 | 8.73 | 19.41 | -48.87 | 20.44 | 53.91 | 0.00 |
| Windlas Biotech Ltd | 8.68bn | 667.47m | 16.97bn | 1.35k | 25.59 | -- | 17.34 | 1.95 | 31.46 | 31.46 | 409.16 | -- | -- | -- | -- | 6,450,929.00 | -- | 8.65 | -- | 11.81 | 38.34 | 34.09 | 7.69 | 7.70 | -- | 15.80 | -- | 18.33 | 20.43 | 18.24 | 4.82 | 30.34 | 27.99 | -- |
| Amrutanjan Health Care Ltd | 4.88bn | 569.03m | 18.38bn | 631.00 | 32.31 | -- | 29.07 | 3.76 | 19.68 | 19.68 | 168.85 | -- | -- | -- | -- | 7,736,897.00 | -- | 15.84 | -- | 19.67 | 50.87 | 52.17 | 11.66 | 13.26 | -- | 319.69 | -- | 19.82 | 7.26 | 11.56 | 13.03 | 15.17 | 69.46 | 26.76 |
| Indoco Remedies Ltd | 17.58bn | -1.14bn | 18.67bn | 6.05k | -- | -- | 292.20 | 1.06 | -12.52 | -12.52 | 197.86 | -- | -- | -- | -- | 2,905,519.00 | -- | 4.84 | -- | 6.87 | 71.18 | 65.70 | -6.62 | 5.16 | -- | -0.3334 | -- | 17.11 | -8.38 | 8.51 | -174.89 | -- | 43.53 | -7.79 |
| Morepen Laboratories Ltd | 17.87bn | 994.48m | 21.12bn | 1.81k | 21.24 | -- | 14.33 | 1.18 | 1.81 | 1.81 | 32.65 | -- | -- | -- | -- | 9,850,214.00 | -- | 8.14 | -- | 12.81 | 33.71 | 31.83 | 5.61 | 5.91 | -- | 5.59 | -- | -- | 7.17 | 16.26 | 22.73 | 28.58 | 65.86 | -- |
| Panacea Biotec Ltd | 6.04bn | -72.40m | 21.44bn | 1.29k | -- | 2.59 | 81.72 | 3.55 | -1.18 | -1.18 | 98.44 | 134.92 | 0.4836 | 1.38 | 8.67 | 4,681,039.00 | -0.6085 | 13.08 | -0.8291 | 19.61 | 58.47 | 48.06 | -1.26 | 30.99 | 0.9785 | -14.33 | 0.0271 | 0.00 | -0.0132 | 0.5466 | -613.56 | -- | 48.74 | -- |
| IOL Chemicals and Pharmaceuticals Ltd | 16.47bn | 953.20m | 21.94bn | 2.89k | 23.00 | -- | 14.27 | 1.33 | 3.25 | 3.25 | -- | -- | -- | -- | -- | 5,696,991.00 | -- | 10.26 | -- | 13.42 | 34.43 | 32.57 | 5.79 | 9.33 | -- | 8.05 | -- | 13.68 | -2.51 | 1.88 | -24.82 | -22.49 | 21.61 | 5.92 |
| Solara Active Pharma Sciences Ltd | 12.55bn | -191.10m | 22.08bn | 1.78k | -- | -- | 28.01 | 1.76 | -4.81 | -4.81 | 330.32 | -- | -- | -- | -- | 7,068,733.00 | -- | -3.27 | -- | -5.35 | 51.77 | 39.95 | -1.52 | -6.17 | -- | 0.7946 | -- | -- | -0.4003 | -0.5816 | 100.10 | -65.75 | -31.71 | -- |
| Bliss GVS Pharma Ltd | 8.68bn | 1.09bn | 23.04bn | 966.00 | 21.39 | -- | 15.65 | 2.65 | 10.18 | 10.18 | 80.97 | -- | -- | -- | -- | 8,986,598.00 | -- | 6.04 | -- | 7.54 | 52.65 | 46.33 | 13.18 | 9.45 | -- | 8.44 | -- | 8.27 | 5.13 | 3.27 | 11.72 | -2.82 | 5.18 | 0.00 |
| Hikal Ltd | 16.99bn | 101.00m | 26.33bn | 2.06k | 259.88 | 2.20 | 16.29 | 1.55 | 0.8216 | 0.8216 | 137.81 | 96.86 | 0.7065 | 2.01 | 4.59 | 8,239,573.00 | 0.42 | 4.78 | 0.6016 | 7.00 | 55.49 | 48.00 | 0.5945 | 5.71 | 0.5418 | 1.11 | 0.3639 | 14.83 | 4.21 | 4.29 | 30.46 | 1.46 | -2.77 | 3.13 |
| Unichem Laboratories Ltd | 22.14bn | 2.95bn | 26.43bn | 3.33k | 8.98 | -- | 6.31 | 1.19 | 41.79 | 41.79 | 314.32 | -- | -- | -- | -- | 6,654,374.00 | -- | -0.5598 | -- | -0.6977 | 54.06 | 55.09 | 13.32 | -1.18 | -- | 3.47 | -- | -- | 18.25 | 13.85 | 246.67 | -- | -18.68 | -- |
Data as of Feb 13 2026. Currency figures normalised to Solara Active Pharma Sciences Ltd's reporting currency: Indian Rupee INR
8.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| First Sentier Investors (Singapore)as of 31 Oct 2025 | 1.57m | 3.27% |
| The Caisse de d�p�t et placement du Qu�becas of 31 Dec 2024 | 922.75k | 1.92% |
| Route One Investment Co. LPas of 31 Dec 2024 | 696.93k | 1.45% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Jan 2026 | 566.11k | 1.18% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 220.42k | 0.46% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 185.69k | 0.39% |
| American Century Investment Management, Inc.as of 05 Feb 2026 | 29.36k | 0.06% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 20.85k | 0.04% |
| DFA Australia Ltd.as of 31 Dec 2025 | 2.32k | 0.01% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Dec 2025 | 922.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
